Immunological landscape and clinical management of rectal cancer

Frontiers in Immunology

Volumn 7, Issue FEB, 2016, Pages

  Pérez Ruiz, Elísabeth ^a   Berraondo, Pedro ^b  

^a HOSPITAL COSTA DEL SOL   (Spain)

^b IdiSNA Navarra Institute for Health Research   (Spain)

Author keywords

Chemotherapy; Immune system; Predictive factors; Radiotherapy; Rectal cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR; K RAS PROTEIN; PROTEIN P53; VASCULOTROPIN;

APOPTOSIS; COLORECTAL CANCER; HETEROZYGOSITY LOSS; IMMUNE RESPONSE; IMMUNE STATUS; LYMPHOCYTIC INFILTRATION; MICROSATELLITE INSTABILITY; OVERALL SURVIVAL; PROTEIN EXPRESSION; RECTUM CANCER; SHORT SURVEY; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84962615511     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00061     Document Type: Short Survey

References (39)

1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin (2014) 64:104-17. doi: 10.3322/caac.21220.
2. Clinical Outcomes of Surgical Therapy Study G. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med (2004) 350:2050-9. doi:10.1056/NEJMoa032651.
3. Bonadeo FA, Vaccaro CA, Benati ML, Quintana GM, Garione XE, Telenta MT. Rectal cancer: local recurrence after surgery without radiotherapy. Dis Colon Rectum (2001) 44:374-9. doi:10.1007/BF02234736.
4. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med (2004) 351:1731-40. doi:10.1056/NEJMoa040694.
5. Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol (2006) 24:4620-5. doi:10.1200/JCO.2006.06.7629.
6. Roh MS, Colangelo LH, O'connell MJ, Yothers G, Deutsch M, Allegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol (2009) 27:5124-30. doi:10.1200/JCO.2009.22.0467.
7. Ippolito E, Massaccesi M, Digesu C, Deodato F, Macchia G, Pirozzi GA, et al. Early proctoscopy is a surrogate endpoint of late rectal toxicity in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys (2012) 83:e191-5. doi:10.1016/j.ijrobp.2011.12.046.
8. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol (2005) 23:8688-96. doi:10.1200/JCO.2005.02.1329.
9. Kuremsky JG, Tepper JE, McLeod HL. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys (2009) 74:673-88. doi:10.1016/j.ijrobp.2009.03.003.
10. Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol (2010) 11:835-44. doi:10.1016/S1470-2045(10)70172-8.
11. Habr-Gama A, Perez RO, Proscurshim I, Campos FG, Nadalin W, Kiss D, et al. Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy. J Gastrointest Surg (2006) 10:1319-1328; discussion 1328. doi:10.1016/j.gassur.2006.09.005.
12. Glynne-Jones R, Wallace M, Livingstone JI, Meyrick-Thomas J. Complete clinical response after preoperative chemoradiation in rectal cancer: is a "wait and see" policy justified? Dis Colon Rectum (2008) 51:10-19; discussion 19-20. doi:10.1007/s10350-007-9080-8.
13. Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol (2011) 29:4633-40. doi:10.1200/JCO.2011.37.7176.
14. Topova L, Hellmich G, Puffer E, Schubert C, Christen N, Boldt T, et al. Prognostic value of tumor response to neoadjuvant therapy in rectal carcinoma. Dis Colon Rectum (2011) 54:401-11. doi:10.1007/DCR.0b013e3182070efb.
15. Elsaleh H, Robbins P, Joseph D, Powell B, Grieu F, Menso L, et al. Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer? Radiother Oncol (2000) 56:239-44. doi:10.1016/S0167-8140(00)00184-5.
16. Garcia-Aguilar J, Chen Z, Smith DD, Li W, Madoff RD, Cataldo P, et al. Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg (2011) 254:486-493; discussion 483-492. doi:10.1097/SLA.0b013e31822b8cfa.
17. Zlobec I, Vuong T, Compton CC, Lugli A, Michel RP, Hayashi S, et al. Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Br J Cancer (2008) 98:450-6. doi:10.1038/sj.bjc.6604172.
18. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol (2005) 23:1826-38. doi:10.1200/JCO.2005.00.406.
19. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol (2006) 32:55-64. doi:10.1016/j.ejso.2005.09.010.
20. Sprenger T, Rodel F, Beissbarth T, Conradi LC, Rothe H, Homayounfar K, et al. Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res (2011) 17:1623-31. doi:10.1158/1078-0432.CCR-10-2592.
21. Li M, Li JY, Zhao AL, Gu J. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinomas. Oncology (2007) 73:52-7. doi:10.1159/000120628.
22. Azzoni C, Bottarelli L, Campanini N, Di Cola G, Bader G, Mazzeo A, et al. Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis (2007) 22:115-26. doi:10.1007/s00384-006-0093-x.
23. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 487:330-7. doi:10.1038/nature11252.
24. Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med (2015) 21:1350-6. doi:10.1038/nm.3967.
25. Ishikawa T, Fujita T, Suzuki Y, Okabe S, Yuasa Y, Iwai T, et al. Tumor-specific immunological recognition of frameshift-mutated peptides in colon cancer with microsatellite instability. Cancer Res (2003) 63:5564-72.
26. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 3:991-8. doi:10.1038/ni1102-991.
27. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol (1986) 39:585-9. doi:10.1136/jcp.39.6.585.
28. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 353:2654-66. doi:10.1056/NEJMoa051424.
29. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313:1960-4. doi:10.1126/science.1129139.
30. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity (2013) 39:782-95. doi:10.1016/j.immuni.2013.10.003.
31. Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, Lardon F, et al. Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol (2010) 11:19. doi:10.1186/1471-2172-11-19.
32. Nagtegaal ID, Marijnen CA, Kranenbarg EK, Mulder-Stapel A, Hermans J, Van De Velde CJ, et al. Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect-a histopathological and immunohistochemical study. BMC Cancer (2001) 1:7. doi:10.1186/1471-2407-1-7.
33. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother (2011) 60:319-26. doi:10.1007/s00262-010-0968-0.
34. Deng L, Zhang H, Luan Y, Zhang J, Xing Q, Dong S, et al. Accumulation of foxp3+ T regulatory cells in draining lymph nodes correlates with disease progression and immune suppression in colorectal cancer patients. Clin Cancer Res (2010) 16:4105-12. doi:10.1158/1078-0432.CCR-10-1073.
35. Reimers MS, Engels CC, Putter H, Morreau H, Liefers GJ, Van De Velde CJ, et al. Prognostic value of HLA class I, HLA-E, HLA-G and Tregs in rectal cancer: a retrospective cohort study. BMC Cancer (2014) 14:486. doi:10.1186/1471-2407-14-486.
36. McMullen TP, Lai R, Dabbagh L, Wallace TM, De Gara CJ. Survival in rectal cancer is predicted by T cell infiltration of tumour-associated lymphoid nodules. Clin Exp Immunol (2010) 161:81-8. doi:10.1111/j.1365-2249.2010.04147.x.
37. Szynglarewicz B, Matkowski R, Suder E, Sydor D, Forgacz J, Pudelko M, et al. Predictive value of lymphocytic infiltration and character of invasive margin following total mesorectal excision with sphincter preservation for the high-risk carcinoma of the rectum. Adv Med Sci (2007) 52:159-63.
38. Yasuda K, Nirei T, Sunami E, Nagawa H, Kitayama J. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer. Radiat Oncol (2011) 6:49. doi:10.1186/1748-717X-6-49.
39. Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, et al. Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res (2014) 20:1891-9. doi:10.1158/1078-0432.CCR-13-2830.